Omega-3

Epax will be investing $35 million over the next two years to increase its capacity and innovate in the omega-3 sector. 

Results of the recently published Omega-3 to Reduce the Incidence of Preterm Birth (ORIP) trial showed that supplementation with omega-3 long chain polyunsaturated fatty acids did not lower risk of early preterm delivery. This is leading the researchers to believe a more targeted approach may be necessary. 

Bioriginal is launching a new algae-based omega-3 DHA ingredient in Europe called AlgalPure DHA. 

Even in the face of an equivocal study or two-or concerns over sourcing, regulatory setbacks, and the occasional pharma-driven lawsuit-omega-3s retain a sterling reputation that other supplements can only envy.

The equation the researchers devised might make it possible to determine how much omega-3 EPA and DHA is needed to elevate the omega-3 index to the desired level. 

Amarin Pharma has filed a petition for certiorari asking the Supreme Court to review a decision made by the U.S. Court of Appeals for the Federal Circuit to uphold a 2017 decision of the International Trade Commission (ITC) not to investigate Amarin’s complaints against manufacturers of omega-3 EPA concentrates. 

The United States Patent and Trademark Office granted the Aker BioMarine's patent application 15/040,330, which covers Aker’s Flexitech technology, used to make Superba 2 and Superba Boost krill oil products at its Houston facility.

Amarin Pharma’s recent comments advising FDA not to allow synthetic omega-3 supplements to be dietary supplements is just one more case in which synthetic supplement ingredients are under fire.

In comments submitted to FDA, Amarin Pharma, maker of the omega-3 drug Vascepa, stated its intentions to file a citizen petition to FDA asserting that ethyl ester omega-3s are not legally allowed to be marketed as dietary supplements. 

A recent study published in the Annals of Internal Medicine is dismissive of dietary supplements for preventing mortality and improving cardiovascular disease outcomes. 

 The Orivo origin seal verifies the authenticity of omega-3 fish oil products through testing that determines the product’s marine oil source and origin.

Archer Daniels Midland Company, in collaboration with Qualitas Health, has unveiled a new line of Onavita Algal DHA and Almega EPA blends. 

FDA said it will allow food and supplement companies to use a qualified health claim linking omega-3 fatty acids EPA and DHA with blood pressure benefits.

The goal for softgel manufacturers when handling marine oils like fish and krill oil is to minimize oxidation at all costs.

In a new animal study, researchers tested the effects of a supplement combination of Kyowa Hakko’s Cognizin-brand citicoline and omega-3 fatty acid DHA (DSM’s life’sDHA brand) in mice who were subjected to bilateral common carotid artery occlusion, resulting in cerebral ischemia.

OmegaQuant’s Omega-3 Index and Prenatal DHA test kits are now registered in the European Union as in vitro medical devices and CE-marked.

Algae’s valuable nutrition stores are prized in today’s human health market.

Amarin Pharma Inc., maker of high-concentration EPA-only omega-3 drug Vascepa, has reached a settlement with omega-3 dietary supplement companies The Coromega Company, Inc., and Omax Health, Inc over complaints the drug company filed in October of 2018.

Here’s what the latest research shows about five of the market’s fastest-growing cognitive performance ingredients.

Amarin, maker of the omega-3 drug Vascepa, has failed in its attempt to get an investigation launched against several omega-3 dietary supplement products and suppliers.

A study recently published in Circulation is challenging our understanding about the effect high levels of omega-6 fatty acids have on human health. 

A recent study published in The Journal of Nutrition shows that fish oil supplementation during the third trimester of pregnancy increased gestational age, size of gestational age, and the birth weight of infants. 

The Global Organization for EPA and DHA Omega-3s (GOED) has launched the GOED Proud Member logo. 

The European Medicines Agency (EMA) has confirmed its previous recommendation to no longer recommend the use of omega-3 fatty acids for secondary prevention of myocardial infarction, following a request for re-examination.

The heart health category remains important to the dietary supplement industry because it includes a stable of products that have proven efficacy and consistent usage.